510 related articles for article (PubMed ID: 31430369)
1. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
[TBL] [Abstract][Full Text] [Related]
2. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
[TBL] [Abstract][Full Text] [Related]
3. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
4. Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Tsai MS; Sun HY; Chen CP; Lee CH; Lee CY; Liu CE; Tang HJ; Hung TC; Li CW; Lee YT; Liou BH; Yang CJ; Hung CC;
Int J Infect Dis; 2023 Jan; 126():39-47. PubMed ID: 36384186
[TBL] [Abstract][Full Text] [Related]
5. Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
Acosta RK; Chen GQ; Chang S; Martin R; Wang X; Huang H; Brainard D; Collins SE; Martin H; White KL
J Antimicrob Chemother; 2021 Jul; 76(8):2153-2157. PubMed ID: 33880558
[TBL] [Abstract][Full Text] [Related]
6. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
Orkin C; Antinori A; Rockstroh JK; Moreno-Guillén S; Martorell CT; Molina JM; Lazzarin A; Maggiolo F; Yazdanpanah Y; Andreatta K; Huang H; Hindman JT; Martin H; Pozniak A
AIDS; 2024 Jun; 38(7):983-991. PubMed ID: 38349226
[TBL] [Abstract][Full Text] [Related]
7. High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
Sax PE; Andreatta K; Molina JM; Daar ES; Hagins D; Acosta R; D'Antoni ML; Chang S; Martin R; Liu H; Blair C; McNicholl I; Gallant J; Collins SE; Martin H; White KL
AIDS; 2022 Sep; 36(11):1511-1520. PubMed ID: 35466963
[TBL] [Abstract][Full Text] [Related]
8. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.
Iwuji CC; Churchill D; Bremner S; Perry N; To Y; Lambert D; Bruce C; Waters L; Orkin C; Geretti AM
BMC Infect Dis; 2020 Jul; 20(1):524. PubMed ID: 32689975
[TBL] [Abstract][Full Text] [Related]
9. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine.
Wohl D; Clarke A; Maggiolo F; Garner W; Laouri M; Martin H; Quirk E
Patient; 2018 Oct; 11(5):561-573. PubMed ID: 29956087
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Daar ES; DeJesus E; Ruane P; Crofoot G; Oguchi G; Creticos C; Rockstroh JK; Molina JM; Koenig E; Liu YP; Custodio J; Andreatta K; Graham H; Cheng A; Martin H; Quirk E
Lancet HIV; 2018 Jul; 5(7):e347-e356. PubMed ID: 29925490
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Grau S; Miró JM; Olalla J; Alcalá JC; Castro A; Rubio-Rodríguez D; Rubio-Terrés C
Expert Rev Anti Infect Ther; 2023 Jan; 21(1):65-76. PubMed ID: 36399521
[TBL] [Abstract][Full Text] [Related]
12. Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.
DeKoven S; Naccarato M; Brumme CJ; Tan DHS
HIV Med; 2023 Nov; 24(11):1137-1143. PubMed ID: 37317505
[TBL] [Abstract][Full Text] [Related]
13. Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Acosta RK; Willkom M; Martin R; Chang S; Wei X; Garner W; Lutz J; Majeed S; SenGupta D; Martin H; Quirk E; White KL
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803969
[TBL] [Abstract][Full Text] [Related]
14. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Hagins D; Kumar P; Saag M; Wurapa AK; Brar I; Berger D; Osiyemi O; Hileman CO; Ramgopal MN; McDonald C; Blair C; Andreatta K; Collins SE; Brainard DM; Martin H;
J Acquir Immune Defic Syndr; 2021 Sep; 88(1):86-95. PubMed ID: 34397746
[TBL] [Abstract][Full Text] [Related]
15. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
[TBL] [Abstract][Full Text] [Related]
16. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
17. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
[TBL] [Abstract][Full Text] [Related]
18. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
[TBL] [Abstract][Full Text] [Related]
19. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.
Stellbrink HJ; Lazzarin A; Woolley I; Llibre JM
HIV Med; 2020 Mar; 21 Suppl 1():3-16. PubMed ID: 32017355
[TBL] [Abstract][Full Text] [Related]
20. Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
Frange P; Veber F; Burgard M; Blanche S; Avettand-Fenoel V
HIV Med; 2024 Feb; 25(2):299-305. PubMed ID: 37807595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
